Study #2023-0257
A phase 1/2 exploratory study of the TBL1 inhibitor, tegavivint(BC2059), in patients with advanced hepatocellular carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Tegavivint, Pembrolizumab
Description
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Hepatocellular Carcinoma
Study phase:
Physician name:
Ian Hu
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.